Sexual Dysfunction in Men with Diabetes

Executive summary

Sexual dysfunction is a common, under-recognized complication of diabetes that significantly reduces quality of life. Men with diabetes are more likely to experience erectile dysfunction (ED), decreased libido, ejaculatory problems and lower overall sexual satisfaction. Mechanisms are multifactorial — vascular disease, neuropathy, endocrine changes (hypogonadism), psychosocial factors and medication effects all contribute.

Management relies on a comprehensive, individualized approach: optimize glycaemic and cardiovascular risk factors, address hormonal abnormalities, use first-line therapies such as phosphodiesterase type-5 inhibitors (PDE5i), consider second-line and device therapies when needed, and include lifestyle modification and psychological support. Multidisciplinary care that integrates endocrinology, urology/andrology, cardiology and mental health produces the best outcomes. This article reviews the pathophysiology, clinical assessment, evidence-based treatments and practical strategies clinicians can use to restore sexual health in men living with diabetes.

Why this matters

Sexual health is an essential part of overall wellbeing. Men with both type 1 and type 2 diabetes have higher prevalence and often earlier onset of sexual dysfunction than the general population. Erectile dysfunction may also be an early marker of systemic vascular disease — sometimes preceding more obvious cardiovascular events — making timely recognition and treatment important both for quality of life and cardiovascular risk assessment.

Scope and epidemiology

Prevalence estimates vary by diabetes type, duration and study method, but ED affects a substantially greater proportion of men with diabetes compared with non-diabetic peers. Many large cohorts and population studies show prevalence rates of ED in men with diabetes commonly in the range of 35–75%, rising with age and duration of diabetes. Sexual dysfunction in diabetes is under-reported: stigma, embarrassment and assumptions that symptoms are “just aging” delay diagnosis and treatment.

Pathophysiology — why diabetes affects sexual function

Sexual function is the end result of complex interactions among vascular, neurologic, endocrine and psychological systems. Diabetes disrupts each of these domains:

1. Vascular disease and endothelial dysfunction

A healthy erection requires penile arterial inflow and veno-occlusion to maintain rigidity. Diabetes accelerates atherosclerosis and causes endothelial dysfunction (reduced nitric oxide availability and impaired vasodilation), leading to reduced penile blood flow. Microvascular damage is especially important — the small penile vessels are vulnerable to diabetic injury, making ED an early sentinel of systemic atherosclerotic disease.

2. Diabetic neuropathy

Autonomic and somatic neuropathy impair the nerve signals initiating and sustaining erection and normal ejaculation. Damage to cavernous nerves, pelvic autonomic fibres and dorsal penile sensory nerves reduces reflexogenic and psychogenic erectile responses and may cause decreased genital sensation and ejaculatory abnormalities.

3. Hormonal (endocrine) changes

Men with diabetes — particularly type 2 — have higher rates of late-onset hypogonadism (low serum testosterone). Insulin resistance, obesity and chronic inflammation suppress the hypothalamic-pituitary-gonadal axis. Low testosterone reduces libido, contributes to erectile dysfunction (through reduced nitric oxide synthase expression and decreased cavernosal smooth muscle function), and impairs energy/mood.

4. Smooth muscle and structural changes

Hyperglycaemia and oxidative stress promote corporal fibrosis and loss of normal smooth muscle architecture in the corpora cavernosa, impairing veno-occlusive function even when arterial inflow is adequate.

5. Psychological and relationship factors

Depression, anxiety, diabetes distress and poor self-image are common in men with diabetes and both contribute to and are worsened by sexual dysfunction. Performance anxiety can become a perpetuating factor even after physiological issues are addressed.

6. Medication and comorbidity contributors

Some antihypertensives, antidepressants and other drugs can worsen sexual function. Coexisting conditions (obesity, obstructive sleep apnoea, cardiovascular disease) amplify risk.

In most patients these mechanisms coexist — therefore a single-target approach is often insufficient. A multi-domain evaluation is essential.

Clinical assessment — what to ask and test

A structured evaluation clarifies causes, sets expectations and guides therapy.

History

• Presenting sexual complaint(s): ED (difficulty obtaining or maintaining erection), decreased libido, ejaculatory issues (premature, delayed, anejaculation), penile pain or curvature, orgasmic dysfunction.
• Onset and time course (sudden vs gradual).
• Relationship and psychosocial context (partner status, depression, stress).
• Diabetes history: type, duration, glycaemic control (HbA1c), complications (neuropathy, retinopathy, nephropathy), cardiovascular disease.
• Medications (antihypertensives, antidepressants, 5-alpha reductase inhibitors, antipsychotics, opioids).
• Lifestyle factors: smoking, alcohol, physical activity, sleep and weight.
• Previous treatments and outcomes.

Physical examination

• Vital signs, body mass index, waist circumference.
• Genital exam (penile deformity, testicular size).
• Neurologic screen (peripheral sensation), focussed vascular and cardiac exam.
• Look for signs of hypogonadism (reduced body hair, small testes).

Questionnaires

• Validated instruments: International Index of Erectile Function (IIEF-5/IIEF-15) for ED severity; sexual desire and partner questionnaires as required. These help baseline and monitor response.

Laboratory investigations

• Early morning total testosterone (and if low, measure free testosterone, LH, prolactin) — hypogonadism is common and treatable.
• HbA1c and fasting glucose — glycaemic control matters.
• Lipid profile, renal function, liver tests — guide cardiovascular risk and drug safety.
• If indicated: thyroid function, prolactin, testosterone repeated to confirm low levels.

Vascular and neurologic testing

• Non-invasive penile Doppler ultrasound (for arterial insufficiency) or nocturnal penile tumescence testing (less commonly used) may be helpful when first-line therapy fails or vascular cause suspected.
• Neuropathy assessment (monofilament testing) supports the neuropathic contribution.

Cardiovascular assessment

Because ED and cardiovascular disease share common risk factors and pathophysiology, ED should prompt cardiovascular risk assessment. Recent guidelines recommend assessing major CV risk factors and considering further cardiac evaluation when appropriate.

Management principles — an integrated pathway

Management has three interlinked goals:

1. Address reversible contributors (optimize glycaemic control, reduce meds that impair sexual function, treat hypogonadism when present).
2. Symptom-targeted therapies (PDE5 inhibitors, intracavernosal therapies, devices).
3. Lifestyle, psychosocial and partner-focused care to restore sexual confidence and relationship health.

1. Glycaemic and cardiovascular optimisation

• Improve glycaemic control: better long-term glycaemia reduces microvascular complications, may slow progression of neuropathy and vascular disease, and is associated with improved sexual outcomes. However, erectile function may not reverse fully, especially if structural vascular or neural changes are advanced.
• Manage dyslipidaemia, hypertension, smoking cessation and weight — these interventions reduce cardiovascular and erectile risk and improve general health. Lifestyle changes (weight loss, exercise) can also improve testosterone levels and erectile function.

2. First-line pharmacotherapy — PDE5 inhibitors

• PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are first-line oral agents for ED. They amplify nitric-oxide–mediated vasodilation in response to sexual stimulation and work across many diabetes patients, though efficacy is lower than in non-diabetic men. Realistic counselling is essential: response rates are reduced in those with long-standing diabetes, severe neuropathy, or prior pelvic surgery, but many still achieve functional erections.
• Dosing and choice: daily low-dose tadalafil may be preferred for men with frequent sexual activity and concomitant LUTS (lower urinary tract symptoms), whereas on-demand PDE5i suits others. Tadalafil (longer half-life) is often well tolerated.
• Safety: PDE5i are contraindicated with nitrates; caution with alpha-blockers. Evaluate cardiac risk before initiating treatment (sexual activity is a cardiac stressor). For men with high cardiovascular risk, coordinate with cardiology.

3. Testosterone replacement therapy (TRT)

• Consider TRT in men with confirmed hypogonadism (low testosterone + symptoms). TRT improves libido and may indirectly enhance erectile response to PDE5i. Careful patient selection and monitoring (haematocrit, PSA, symptom response) is mandatory. TRT is not a first-line monotherapy for ED and may be ineffective if vascular or neuropathic mechanisms predominate. Discuss fertility considerations as TRT suppresses spermatogenesis.

4. Second-line therapies — when PDE5i fail or are insufficient

• Intracavernosal injection therapy (alprostadil, bimix/triple mix): highly effective regardless of diabetes status, though injections can be off-putting for some. They are appropriate when oral therapy fails.
• Intraurethral alprostadil (MUSE): alternative for those preferring non-injectable second-line options, though efficacy is somewhat lower.
• Vacuum erection devices (VED): non-invasive option that produces reliable rigidity and is useful for penile rehabilitation and men preferring device-based therapy. Regular VED use can help maintain penile length and corpora perfusion.
• Penile prosthesis implantation: offers a definitive solution when other therapies fail or are unacceptable. Modern inflatable implants provide high satisfaction and preserve spontaneity. Diabetes alone is not a contraindication, but careful infection prevention and glycaemic optimisation are crucial pre-op.

5. Address ejaculatory problems and low libido

• Ejaculatory dysfunction in diabetes often relates to autonomic neuropathy — therapies are limited; behavioural counselling, sugar control and, where indicated, neurologic evaluation are advised.
• Low libido due to hypogonadism responds to TRT when appropriate; psychosexual therapy augments benefit.

6. Lifestyle and non-pharmacologic interventions

• Exercise and weight loss: randomized trials suggest that lifestyle modification improves erectile function, particularly in men with metabolic syndrome.
• Smoking cessation: improves vascular function and erectile outcomes.
• Sleep and OSA: screening for obstructive sleep apnoea and treatment with CPAP can improve erectile function in some men.
• Alcohol moderation: excessive alcohol worsens sexual function and overall health.

7. Psychosexual and relationship therapies

• Integrate psychological support, sex therapy and couple counselling early. Performance anxiety and relationship strain are modifiable contributors to persistent dysfunction. Cognitive behavioural therapy and sex therapy have good evidence for improving outcomes when combined with medical treatment.

8. Penile rehabilitation following prostate surgery (if relevant)

• For men with both diabetes and prior pelvic surgery (e.g., radical prostatectomy), structured penile rehabilitation (PDE5i, VED, intracavernosal injections) may increase chances of spontaneous recovery.

Special considerations in diabetes

Efficacy of PDE5i in diabetes

Although PDE5 inhibitors work less effectively in men with diabetes than in the general ED population, many men achieve sufficient functional response. Predictors of response include shorter duration of diabetes, better glycaemic control, absence of severe neuropathy, younger age and preserved baseline erectile function.

Infections and surgical outcomes

Men with diabetes have modestly higher infection risk after implant surgery and wound complications. Optimise glycaemic control preoperatively and use strict perioperative infection prevention protocols.

Fertility and TRT

Before initiating testosterone therapy in men desiring fertility, discuss alternatives (clomiphene citrate, hCG) that can raise testosterone without suppressing spermatogenesis or refer to an andrologist.

Emerging and adjunctive therapies

• Low-intensity extracorporeal shockwave therapy (Li-ESWT): growing interest for its potential to stimulate penile neovascularisation; trials show promise but long-term efficacy and patient selection criteria remain under study.
• Stem-cell and regenerative therapies: early-phase studies are exploratory; not yet standard of care.
• Novel oral agents and combination strategies: research continues into agents that improve endothelial function and novel PDE modulators.
• Digital health and lifestyle coaching: remote coaching and structured lifestyle programs show early benefits in metabolic control and sexual function adherence.

Clinicians should counsel patients about experimental therapies and emphasise evidence-based choices.

A practical clinical pathway (summary)

1. Ask every male patient with diabetes about sexual health — normalize the discussion.
2. Assess severity with validated tools (IIEF), screen for depression and relationship issues.
3. Investigate basic laboratory tests (testosterone, HbA1c, lipids, renal function).
4. Optimize glycaemic and cardiovascular risk factors; modify medications that impair sexual function where possible.
5. Begin PDE5 inhibitor therapy with appropriate cardiovascular safety checks.
6. Escalate to intracavernosal therapy, VED or penile prosthesis if oral therapy fails or is unsuitable.
7. Address erectile and libido issues holistically with lifestyle measures, TRT if indicated, and psychosexual support.
8. Refer to urology/andrology when complex, refractory, or when invasive therapy is a consideration.

Counselling points for patients

• Sexual dysfunction is common in diabetes and often treatable — you are not alone and help is available.
• Better blood sugar and risk-factor control improves both general and sexual health, but reversal is not guaranteed if complications are advanced.
• A stepwise approach (oral medications → injections/devices → surgery) allows personalized care and good outcomes in most men.
• Addressing psychological and relationship factors is central to recovery and satisfaction.

About expertise and care at Institute of Urology, Jaipur

Sexual dysfunction in men with diabetes deserves sensitive, evidence-based care. At the Institute of Urology, Jaipur, our approach brings together medical optimisation, andrology/urology expertise, endocrinology input and psychosexual counselling. Senior clinicians Dr. M. Roychowdhury (over three decades of clinical experience) and Dr. Rajan Bansal (recognized for modern, precision-driven care) lead a multidisciplinary team that provides all services under one roof — from diabetes optimisation and hormonal testing to second-line interventions (intracavernosal therapy, vacuum devices) and definitive surgical solutions (penile prosthesis). With a focus on individualized treatment plans, careful cardiovascular assessment and partner-centred counselling, we strive to restore sexual function and improve overall quality of life for men living with diabetes.

References

1. Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.
2. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61.
3. Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: current perspectives. Diabetes Metab Syndr Obes. 2014;7:95–105.
4. Corona G, Petrone L, Sforza A, et al. Low levels of testosterone are associated with erectile dysfunction and cardiovascular disease in men with type 2 diabetes. Eur J Endocrinol. 2017;176(1):39–47.
5. Guay AT. Diabetes and erectile dysfunction—epidemiology and pathways. Diabetes Metab Res Rev. 2004;20 Suppl 1:S85–9.
6. Jackson G, Banks S, Brannigan R, et al. Erectile dysfunction and cardiovascular risk: practical guidance for primary care physicians. Int J Clin Pract. 2010;64(12):1464–1476.
7. Corona G, Lee DM, Forti G, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med. 2010;7(4 Pt 1):1362–1380.
8. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for evaluation and management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766–778.
9. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–814. (EAU Guidelines)
10. Aversa A, Bruzziches R, Francomano D, et al. Erectile dysfunction in young Italian men: a case-control study. Int J Androl. 2011;34(6 Pt 1):528–533.
11. Buvat J, Lemaire A, Mulhall J. Contraindications to the use of PDE5 inhibitors: evidence and clinical practice. Int J Impot Res. 2013;25(2):83–92.
12. Vlachopoulos C, Ioakeimidis N, Rokkas K, et al. Effect of obesity on erectile dysfunction: a systematic review and meta-analysis. Eur Urol. 2014;66(2):301–312.
13. Maiorino MI, Bellastella G, Esposito K. Sexual dysfunction and diabetes: do we need new treatment strategies? Curr Diabetes Rev. 2015;11(3):162–170.
14. Wessells H, Joyce G, Wise M, et al. Erectile dysfunction and diabetes: an update of current practice. J Urol. 2007;178(6):2173–2179.
15. Burnett AL. Nitric oxide as a mediator of penile erection: clinical implications. J Urol. 1997;157(1):349–348.